Publications 2013

Serum microRNAs as biomarkers of human lymphocyte activation in health and disease
de Candia P. Torri A, Pagani M, Abrignani S.
Front Immunol. 2014 Feb 10;5:43. .

Absence of a role for interleukin-13 in inflammatory bowel disease
Biancheri P, Di Sabatino A, Ammoscato F, Facciotti F, Caprioli F, Curciarello R, Hoque SS, Ghanbari A, Joe-Njoku I, Giuffrida P, Rovedatti L, Geginat J, Corazza GR, Macdonald TT
Eur J Immunol. 2014 Feb;44(2):370-85.

Intracellular Modulation, Extracellular Disposal and Serum Increase of MiR-150 Mark Lymphocyte Activation
de Candia P, Torri A, Gorletta T, Fedeli M, Bulgheroni E, Cheroni C, Marabita F, Crosti M, Moro M, Pariani E, Romanò L, Esposito S, Mosca F, Rossetti G, Rossi RL, Geginat J, Casorati G, Dellabona P, Pagani M, Abrignani S.
Plos One, 2013 Sep 26;8(9):e75348.

The CD4-centered universe of human T cell subsets
Geginat J, Paroni M, Facciotti F, Gruarin P, Kastirr I, Caprioli F, Pagani M, Abrignani S.
Semin Immunol. 2013 Nov 15;25(4):252-62.

Human CD1c+ dendritic cells secrete high levels of IL-12 and potently prime cytotoxic T cell responses
Nizzoli G, Krietsch J, Weick A, Steinfelder S, Facciotti F, Gruarin P, Bianco A, Steckel B, Moro M, Crosti M, Romagnani C, Stoelzel K, Torretta S, Pignataro L, Scheibenbogen C, Neddermann P, De Francesco R, Abrignani S, Geginat J.
Blood. 2013 Aug 8;122(6):932-42

Role of microRNAs and long-non-coding RNAs in CD4+ T-cell differentiation.
Pagani M, Rossetti G, Panzeri I, De Candia P, Bonnal R.J.P, Rossi R, Geginat J, Abrignani S.
Immunological Reviews. 2013; 253: 82–96.

Cirrhosis and rapid virological response to peginterferon plus ribavirin determine treatment outcome in HCV-1 IL28b rs12979860 CC patients
Aghemo A, Degasperi E, Rumi MG, Galmozzi E, Valenti L, De Francesco R, De Nicola S, Cheroni C, Grassi E, Colombo M.
BioMed Research International, 2013;2013:580796.

A Hepatitis C Virus (HCV) Vaccine Comprising Envelope Glycoproteins gpE1/gpE2 Derived from a Single Isolate Elicits Broad Cross-Genotype Neutralizing Antibodies in Humans.
Law JL, Chen C, Wong J, Hockman D, Santer DM, Frey SE, Belshe RB, Wakita T, Bukh J, Jones CT, Rice CM, Abrignani S, Tyrrell DL, Houghton M.
PLoS ONE. 2013;8(3):e59776.

Hepatitis C virus-specific directly acting antiviral drugs.
Delang L, Neyts J, Vliegen I, Abrignani S, Neddermann P, De Francesco R.
Current Topics in Microbiology and Immunology. 2013;369:289-320.

New horizons in Hepatitis C antiviral therapy with direct-acting antivirals.
Aghemo A, De Francesco R.
Hepatology. 2013 Jul;58(1):428-38.

Reduction of CD68+ Macrophages and Decreased IL-17 Expression in Intestinal Mucosa of Patients with Inflammatory Bowel Disease Strongly Correlate With Endoscopic Response and Mucosal Healing following Infliximab Therapy.
Caprioli F, Bosè F, Rossi RL, Petti L, Viganò C, Ciafardini C, Raeli L, Basilisco G, Ferrero S, Pagani M, Conte D, Altomare G, Monteleone G, Abrignani S, Reali E.
Inflammatory Bowel Diseases. 2013 Mar-Apr;19(4):729-39.

INGM researches are supported by